NVIVQ (NVIVQ)
| Market Cap | 1.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.33M |
| Shares Out | 3.11M |
| EPS (ttm) | -3.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 930 |
| Open | n/a |
| Previous Close | 0.370 |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NVIVQ
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and... [Read more]
Financial Performance
Financial StatementsNews
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord i...
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 1...
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Reverse Stock Split
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized ...
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of Preclinical Module For Neuro-Spinal Implant
The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) appl...
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company's Complete HDE Submission
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord ...
InVivo Therapeutics Announces Publication in Peer-Reviewed Journal of Neurosurgery: Spine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the recent publication of a peer-reviewed manuscript in the Journal of Neurosurgery: Spine describi...
InVivo Therapeutics Announces Closing of $15.0 Million Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the closing of its previously announced public offering of 18,750,000 shares of its common stock (o...
InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp.